The decline of antibiotic era - new approaches for antibacterial drug discovery

• Autorzy: Jagusztyn-Krynicka E K , Wyszynska A.
• Języki publikacji: EN

Abstrakty

EN

Infectious diseases still remain the main cause of human premature deaths; especially in developing countries. The emergence and spread of pathogenic bacteria resistant to many antibiotics (multidrug-resistant strains) have created the need for the development of novel therapeutic agents. Only two new classes of antibiotics of novel mechanisms of action (linezolid and daptomycin) have been introduced into the market during the last three decades. The recent progress in molecular biology and bacterial genome analysis has had an enormous impact on antibacterial drug research. This review presents new achievements in searching a new bacterial essential genes, a potential targets for antibacterial drugs. Application of metagenomics strategy is also shown. Some recent technologies aimed at development of anti-pathogenic drugs such as inhibitors of quorum sensing process or histidine kinases are also discussed. Extensive research efforts have provided many details concerning structure of bacterial proteins playing an important role in pathogenesis such as adherence proteins or toxins, what allowed searching for antitoxin drugs or drugs interfering with bacterial adhesion. As an example, the review focuses on anthrax therapies under development. Additionally, the article presents the progress in phage therapy; using bacteriophages or their products such as lysins in antibacterial therapy.

Słowa kluczowe

EN

infectious disease; microbial infection; horizontal gene transfer; human disease; genomics; antibiotic resistance; protein structure; bacteriophage; antibiotic; antibiotic new class; antibacterial drug; antibacterial therapy

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2008
• Tom: 57
• Numer: 2
• Opis fizyczny: p.91-98,ref.

Twórcy

autor

Jagusztyn-Krynicka E K

• University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland

autor

Wyszynska A.

Bibliografia

• Adams J.M. 1968. On the release of the formyl group from nascent protein. J. Mol. Biol. 33: 571-589.
• Basha S., P. Rai, V. Poon, A. Saraph, K. Gujraty, M.Y. Go, S. Sadacharan, M. Frost, J. Mogridge and R.S. Kane. 2006. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. USA 103: 13509-13513.
• Beier D. and R. Gross. 2006. Regulation of bacterial virulence by two-component systems. Curr. Opin. Microbiol. 9: 143-152.
• Cazzola M., M.G. Matera and C.P. Page. 2003. Novel approaches to the treatment of pneumonia. Trends Pharmacol. Sci. 24: 306-314.
• Chan M.K., W. Gong, P.T. Rajagopalan, B. Hao, C.M. Tsai and D. Pei. 1997. Crystal structure of the Escherichia coli peptide deformylase. Biochemistry 36: 13904-13909.
• Cheng Q., D. Nelson, S. Zhu and V.A. Fischetti. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49: 111-117.
• Davies D. 2003. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2: 114-122.
• de Zoete M.R., J.P. van Putten and J.A. Wagenaar. 2007. Vaccination of chickens against Campylobacter. Vaccine 25: 5548-5557.
• Founder P.E., D. Vallenet, V. Barbe, S. Audic, H. Ogata, L. Poirel, H. Richet, C. Robert, S. Mangenot, C. Abergel and others. 2006. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2: e7.
• Freiberg C. and H. Brotz-Oesterhelt. 2005. Functional genomics in antibacterial drug discovery. Drug Discov. Today 10: 927-935.
• Girard V. and M. Mourez. 2006. Adhesion mediated by auto-transporters of Gram-negative bacteria: structural and functional features. Res. Microbiol. 157: 407-416.
• Handelsman J. 2004. Metagenomics: application of genomics to uncultured microorganisms. Microbiol. Mol. Biol. Rev. 68: 669-685.
• Havelaar A.H., M.J. Mangen, A.A. de Koeijer, M.J. Bogaardt, E.G. Evers, W.F. Jacobs-Reitsma, W. van Pelt, J.A. Wagenaar, G.A. de Wit, H. van der Zee and others. 2007. Effectiveness and efficiency of controlling Campylobacter on broiler chicken meat. Risk. Anal. 27: 831-844.
• Karginov V.A., E.M. Nestorovich, M. Moayeri, S.H. Leppla and S.M. Bezrukov. 2005. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc. Natl. Acad. Sci. USA 102: 15075-15080.
• Karginov V.A., E.M. Nestorovich, A. Yohannes, T.M. Robinson, N.E. Fahmi, F. Schmidtmann, S.M. Hecht and S.M. Bezrukov. 2006. Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob. Agents Chemother. 50: 3740-3753.
• Liu J., M. Dehbi, G. Moeck, F. Arhin, P. Bauda, D. Bergeron, M. Callejo, V. Ferretti, N. Ha, T. Kwan and others. 2004. Antimicrobial drug discovery through bacteriophage genomics. Nat. Biotechnol. 22: 185-191.
• Lyczak J.B., C.L. Cannon and G.B. Pier. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes. Infect. 2: 1051-1060.
• Marraffini L.A., A.C. Dedent and O. Schneewind. 2006. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. Microbiol. Mol. Biol. Rev. 70: 192-221.
• Matsushita M. and K.D. Janda. 2002. Histidine kinases as targets for new antimicrobial agents. Bioorg. Med. Chem. 10: 855-867.
• Moayeri M. and S.H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7: 19-24.
• Mourez M., D.B. Lacy, K. Cunningham, R. Legmann, B.R. Sellman, J. Mogridge and R.J. Collier. 2002. 2001: a year of major advances in anthrax toxin research. Trends Microbiol. 10: 287-293.
• Niemann H.H., W.D. Schubert and D.W. Heinz. 2004. Adhesins and invasins of pathogenic bacteria: a structural view. Microbes Infect. 6: 101-112.
• Parsek M.R. and P.K. Singh. 2003. Bacterial biofilms: an emerging link to disease pathogenesis. Annu. Rev. Microbiol. 57: 677-701.
• Petty N.K., T.J. Evans, P.C. Fineran and G.P. Salmond. 2007. Biotechnological exploitation of bacteriophage research. Trends Biotechnol. 25: 7-15.
• Piatek R., B. Zalewska, K. Bury and J. Kur. 2005. The chaper-one-usher pathway of bacterial adhesin biogenesis - from molecular mechanism to strategies of anti-bacterial prevention and modern vaccine design. Acta Biochim. Pol. 52: 639-646.
• Pucci M.J. 2006. Use of genomics to select antibacterial targets. Biochem. Pharmacol. 71: 1066-1072.
• Rainey G.J. and J.A. Young. 2004. Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2: 721-726.
• Rasmussen T.B. and M. Givskov. 2006. Quorum-sensing inhibitors as anti-pathogenic drugs. Int. J. Med. Microbiol. 296: 149-161.
• Roberts M.C. 2006. Multidrug-resistant genes are associated with an 86-kb island in Acinetobacter baumannii. Trends Microbiol. 14: 375-378.
• Sauer F.G., H. Remaut, S.J. Hultgren and G. Waksman. 2004. Fiber assembly by the chaperone-usher pathway. Biochim. Biophys. Acta 1694: 259-267.
• Scobie H.M., J.M. Marlett, G.J. Rainey, D.B. Lacy, R.J. Collier and J.A. Young. 2007.. Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation. PLoS ONE 2: e329.
• Sizemore D.R., B. Warner, J. Lawrence, A. Jones and K.P. Killeen. 2006. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine 24: 3793-3803.
• Skurnik M. and E. Strauch. 2006. Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296: 5-14.
• Taylor L.H., S.M. Latham and M.E. Woolhouse. 2001. Risk factors for human disease emergence. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356: 983-989.
• Venturi V. 2006. Regulation of quorum sensing in Pseudomonas. FEMS Microbiol. Rev. 30: 274-291.
• Wang W., R. White and Z. Yuan. 2006. Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 1656-1663.
• Welch T.J., W.F. Fricke, P.F. McDermott, D.G. White, M.L. Rosso, D.A. Rasko, M.K. Mammel, M. Eppinger, M.J. Rosovitz, D. Wagner and others. 2007. Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS ONE 2: e309.
• Whitehead N.A., A.M. Barnard, H. Slater, N.J. Simpson and G.P. Salmond. 2001. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol. Rev. 25: 365-404.
• Woolhouse M.E. 2002. Population biology of emerging and re-emerging pathogens. Trends Microbiol. 10: S3-7.
• Wright G.D. 2007. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 5: 175-186.
• Wyszynska A., A. Raczko, M. Lis and E.K. Jagusztyn-Krynicka. 2004. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine 22: 1379-1389.
• Yoong P., R. Schuch, D. Nelson and V.A. Fischetti. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus jaecalis and Enterococcus faecium. J. Bacterial. 186: 4808-4812.
• Yoong P., R. Schuch, D. Nelson and V.A. Fischetti. 2006. PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J. Bacterial. 188: 2711-2714.
• Yuan Z., J. Trias and R.J. White. 2001. Deformylase as a novel antibacterial target. Drug Discov. Today 6: 954-961.
• Yuan Z. and R.J. White. 2006. The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. Biochem. Pharmacol. 71: 1042-1047.